ESTRO 2024 - Abstract Book

S119

Invited Speaker

ESTRO 2024

Conclusion

In this study on dose escalation for LA-NSCLC, the treatment was well-tolerated and feasible. Dose escalation was determined safe in the pre-planned interim analyses.

We are looking forward to present the data on the primary end point.

3532

The oncologist, for immunotherapy

Silke Tribius

Asklepios Tumorzentrum Hamburg, Radiation Oncology, Hamburg, Germany

Abstract:

Introduction of immunotherapy for various malignancies has lost its threat as being a death sentence to many patients.